

# Cyclopiazonic acid reduces the coupling factor of the $\text{Ca}^{2+}$ -ATPase acting on $\text{Ca}^{2+}$ binding

Francisco Martínez-Azorín\*

Departamento de Bioquímica (B-19), Facultad de Medicina (CSIC-UAM), Universidad Autónoma de Madrid, Arturo Duperier 4, E-28029 Madrid, Spain

Received 30 June 2004; revised 6 August 2004; accepted 30 August 2004

Available online 11 September 2004

Edited by Peter Brzezinski

**Abstract** The mycotoxin cyclopiazonic acid (CPA) is a potent inhibitor of the sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase. The compound decreases the affinity of the  $\text{Ca}^{2+}$ -ATPase for  $\text{Ca}^{2+}$  and reduces the maximum specific activity of the enzyme. Furthermore, CPA abolishes the cooperativity of  $\text{Ca}^{2+}$  transport, showing a  $\text{Ca}^{2+}$ /ATP ratio  $\sim 1$  at any extent of  $\text{Ca}^{2+}$  saturation. There is also an effect on the  $\text{Ca}^{2+}$ -binding mechanism, where the addition of CPA results in binding of only half-maximal amount of  $\text{Ca}^{2+}$  observed in its absence. The experimental data suggest that in the presence of CPA, only a single  $\text{Ca}^{2+}$  ion binds to the  $\text{Ca}^{2+}$ -ATPase.

© 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

**Keywords:**  $\text{Ca}^{2+}$ -ATPase; Sarcoplasmic reticulum; Inhibition; CPA;  $\text{Ca}^{2+}$ -binding; Coupling factor

## 1. Introduction

Sarcoplasmic reticulum (SR)  $\text{Ca}^{2+}$ -ATPase is a 110-kDa membrane protein that consists of 10 transmembrane helices (M1–M10), three cytoplasmic domains and small luminal loops. SR  $\text{Ca}^{2+}$ -ATPase is a calcium pump transporting two mol of  $\text{Ca}^{2+}$  across the SR membrane by hydrolytic coupling with one mol of ATP. According to the  $\text{E}_1/\text{E}_2$  theory [1], the enzyme with bound  $\text{Ca}^{2+}$  ( $\text{E}_1$ ) is autophosphorylated by ATP to form  $\text{E}_1\text{P}$ . This phosphorylation causes the bound  $\text{Ca}^{2+}$  ions to be occluded at the transport sites and the subsequent conformational transition to the  $\text{E}_2\text{P}$  form releases  $\text{Ca}^{2+}$  into the lumen. Finally, dephosphorylation takes place and returns the enzyme into the unphosphorylated and  $\text{Ca}^{2+}$ -unbound  $\text{E}_2$  form.

Cyclopiazonic acid (CPA), a mycotoxin produced by certain strains of *Penicillium cyclopium* and *Aspergillus flavus* [2], is a specific and potent inhibitor of sarco-endoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase [3–5]. The specificity of CPA for SR  $\text{Ca}^{2+}$ -ATPase and not for other cation ATPases was also established

[4]. The affinity of SR  $\text{Ca}^{2+}$ -ATPase for CPA is dependent on the conformational state of the enzyme, being high in the absence of  $\text{Ca}^{2+}$  but low in its presence [5], because CPA binds to the  $\text{Ca}^{2+}$ -ATPase  $\text{E}_2$  intermediate and block enzyme turnover [6]. ATP protected the enzyme against inhibition by CPA, while  $\text{Ca}^{2+}$  had only moderate effect on the extent of inhibition [4]. Thus, CPA decreases enzyme affinity for ATP but do not compete for the same binding site [6], because the CPA binding domain is in the S3 stalk segment (cytoplasmic prolongation of M3) of the  $\text{Ca}^{2+}$ -ATPase [7].

The present work shows that binding of CPA to the  $\text{Ca}^{2+}$ -ATPase results in an uncoupling of ATPase activity by changing the extent of  $\text{Ca}^{2+}$  binding, from the usual two  $\text{Ca}^{2+}$  ions per ATPase molecule to one.

## 2. Materials and methods

### 2.1. Materials

[ $^3\text{H}$ ]Glucose and  $^{45}\text{CaCl}_2$  were obtained from DuPont NEM. A stock solution of CPA from *Penicillium cyclopium* (Sigma) was prepared in ethanol. The volume of ethanol added did not exceed 1% of the total volume.

### 2.2. Sample preparation

A microsomal fraction of SR membrane enriched in  $\text{Ca}^{2+}$ -ATPase protein was isolated from rabbit leg white muscle as previously described [8]. The protein content was estimated by the method of Lowry et al. [9] using bovine serum albumin (BSA) as a standard.

### 2.3. Free $\text{Ca}^{2+}$ concentration

Reaction media with different free  $\text{Ca}^{2+}$  concentration were prepared with the aid of a  $\text{Ca}^{2+}$ -EGTA buffer according to a computer program [10] that takes into consideration the association constant for the  $\text{Ca}^{2+}$ -EGTA complex [11] and the equilibrium constants for the EGTA protonation [12].

### 2.4. ATPase activity

The rate of ATP hydrolysis was measured at room temperature following the liberation of inorganic phosphate (Pi) [13]. ATPase activity was assayed in a reaction mixture containing 0.05 mg of SR/ml, 20 mM Mops (pH 7), 80 mM KCl, 5 mM  $\text{MgCl}_2$ , 5 mM potassium oxalate, 1 mM EGTA, 0.967 mM  $\text{CaCl}_2$  (pCa 5) and different CPA concentrations. After 5 min of incubation, the reaction was started by the addition of 1 mM ATP. The rates of Pi release were calculated from the initial phase of time course plots.  $\text{Ca}^{2+}$ -independent ATPase activity was assayed in the presence of 2 mM EGTA and no added  $\text{Ca}^{2+}$ . The  $\text{Ca}^{2+}$ -dependent ATPase activity was estimated by subtracting the  $\text{Ca}^{2+}$ -independent ATPase from the total activity. The  $\text{Ca}^{2+}$  dependence of the ATPase activity was measured in presence of 1 mM EGTA and different  $\text{Ca}^{2+}$  concentrations to yield the desired free concentration.

\* Fax: +34 91 585 4401.

E-mail address: fazorin@iib.uam.es (F. Martínez-Azorín).

**Abbreviations:** CPA, cyclopiazonic acid; SR, sarcoplasmic reticulum; Pi, inorganic phosphate; pCa, negative logarithm of the molar free  $\text{Ca}^{2+}$  concentration

### 2.5. $\text{Ca}^{2+}$ transport

The active transport of  $\text{Ca}^{2+}$  was measured at room temperature by the radioactive tracer method. The incubation medium included 0.05 mg of SR/ml, 20 mM Mops (pH 7), 80 mM KCl, 5 mM  $\text{MgCl}_2$ , 5 mM potassium oxalate, 1 mM EGTA, different  $^{45}\text{CaCl}_2$  (~4000 cpm/nmol), 0 or 0.75  $\mu\text{M}$  CPA and 1 mM ATP. The  $\text{Ca}^{2+}$  accumulated inside the vesicles was determined by filtering aliquots of 1 ml (0.05 mg of protein) on HAWP Millipore filters (0.45  $\mu\text{m}$ ) at serial time intervals. The filters were rinsed with 3 ml of medium containing 20 mM Mops (pH 7), 80 mM KCl, 5 mM  $\text{MgCl}_2$  and 1 mM  $\text{LaCl}_3$  before counting the  $^{45}\text{Ca}^{2+}$  retained on the filters. The rates of  $\text{Ca}^{2+}$  transport were calculated from the initial phase of time course plots.

### 2.6. $\text{Ca}^{2+}$ binding

The high affinity  $\text{Ca}^{2+}$  binding was measured by the double-labeling filtration technique [14]. The enzyme (0.3 mg of SR/ml) was incubated at room temperature in a medium consisting of 20 mM Mops (pH 7), 80 mM KCl, 5 mM  $\text{MgCl}_2$ , 69.4  $\mu\text{M}$  EGTA, 1 mM [ $^3\text{H}$ ]Glucose (~1000 cpm/nmol), different concentrations of CPA and 100  $\mu\text{M}$   $^{45}\text{CaCl}_2$  (~5000 cpm/nmol; pCa 4.5). After equilibration for 5 min, aliquots of 0.2 ml (0.06 mg of protein) were placed onto filters (Millipore HAWP 0.45  $\mu\text{m}$ ) previously soaked in unlabeled medium and subjected to vacuum. Counting of radioactive tracers in the incubation medium and the filters allowed to determine the  $\text{Ca}^{2+}$  bound by subtracting the non-specific free  $\text{Ca}^{2+}$  trapped in each filter ( $^3\text{H}$  labeling).

### 2.7. Measurement of parameters

The curves were fitted to the Hill equation expressed as a function of the  $K_{0.5}$ :

$$Y = N \times \text{Ca}^h / (K_{0.5}^h + \text{Ca}^h)$$

$Y$  being the experimental values,  $N$  the maximum  $\text{Ca}^{2+}$ -ATPase or  $\text{Ca}^{2+}$  transport activities,  $K_{0.5}$  the  $\text{Ca}^{2+}$  concentration needed for half-activity or apparent affinity constant and  $h$  the Hill coefficient.

### 2.8. Data presentation

The experimental values represent the average of at least three independent experiments. The standard deviations of the mean values are given when indicated.

## 3. Results

### 3.1. $\text{Ca}^{2+}$ -ATPase inhibition

**CPA dependence of  $\text{Ca}^{2+}$ -ATPase activity.** The effect of CPA was initially assessed by measuring the hydrolytic capacity of




Fig. 1. Inhibition of the steady-state ATPase activity of  $\text{Ca}^{2+}$ -ATPase by CPA. The  $\text{Ca}^{2+}$ -ATPase activity as a function of CPA concentrations at pCa 5.

the  $\text{Ca}^{2+}$ -transporting ATPase. Thus, SR vesicles in the presence of 5 mM potassium oxalate and increasing concentrations of CPA were preincubated under optimal conditions to measure the  $\text{Ca}^{2+}$ -dependent ATPase activity. As depicted in Fig. 1, the inhibitory effect elicited by CPA was dependent on the concentration used as has been shown previously [3–5,7,15]. These data provide half-inhibition value of approximately 0.2  $\mu\text{M}$ . Thus, assuming from the maximal EP level that 1 mg of SR protein contains ~4 nmol of  $\text{Ca}^{2+}$ -ATPase active sites (data not shown) [16], it can be deduced a drug:enzyme molar ratio ~1:1 at 0.2  $\mu\text{M}$ .

**$\text{Ca}^{2+}$ -dependence of hydrolytic and transport activities.** Steady-state experiments on ATP hydrolysis and  $\text{Ca}^{2+}$  transport were suitable to provide information on the coupling phenomenon.




Fig. 2. Steady-state experiment of  $\text{Ca}^{2+}$  transport and ATP hydrolysis. (A)  $\text{Ca}^{2+}$  dependence on the  $\text{Ca}^{2+}$ -ATPase activity (●, ■) or  $\text{Ca}^{2+}$  transport (○, □) of  $\text{Ca}^{2+}$ -ATPase measured in the absence (circles) or presence of 0.75  $\mu\text{M}$  (squares) CPA. (B) Plot of  $\text{Ca}^{2+}$  transport versus Pi release measured at different pCa to calculate the coupling factor at 0 (○) or 0.75  $\mu\text{M}$  (□) CPA.

Table 1

Parameters and coupling values describing the  $\text{Ca}^{2+}$ -ATPase activity and  $\text{Ca}^{2+}$ -uptake in the presence and in the absence of 0.75  $\mu\text{M}$  CPA

	Pi release (●, ■)			$\text{Ca}^{2+}$ uptake (○, □)			$\text{Ca}^{2+}$ /Pi coupling
	$K_{0.5}$ ( $\mu\text{M}$ )	$N$ (nmol/mg min)	$h$	$K_{0.5}$ ( $\mu\text{M}$ )	$N$ (nmol/mg min)	$h$	
Control	0.39	0.93	1.9	0.41	1.63	1.8	1.9
0.75 $\mu\text{M}$ CPA	0.74	0.57	1.1	0.86	0.65	1.1	1.1

The data from Fig. 2 were fitted to Hill equation.

The presence of CPA reduces the apparent affinity ( $K_{0.5}$ ) of the enzyme for  $\text{Ca}^{2+}$  from 0.39  $\mu\text{M}$  in the absence of CPA to 0.74  $\mu\text{M}$  at 0.75  $\mu\text{M}$  CPA (Fig. 2A); therefore, higher  $\text{Ca}^{2+}$  concentration are needed to express the same enzymatic activity. In addition, lower maximum ATPase activities were observed at higher CPA concentrations. Thus, the maximum specific activity of  $\text{Ca}^{2+}$ -ATPase ( $N$ ) was 0.93  $\mu\text{mol/mg min}$  and it was reduced to 0.57  $\mu\text{mol/mg min}$  in presence of 0.75  $\mu\text{M}$  CPA. Meanwhile, the Hill coefficients ( $h$ ) decreased from 1.9 to 1.1 (Table 1).

The effect of CPA on the  $\text{Ca}^{2+}$ -transporting activity is also shown in Fig. 2A. In the absence of CPA, the data could be fitted assuming a  $K_{0.5}$ ,  $N$  and  $h$  values of 0.41  $\mu\text{M}$ , 1.63  $\mu\text{mol/mg min}$  and 1.8, respectively, and in presence of 0.75  $\mu\text{M}$  CPA, 0.86  $\mu\text{M}$ , 0.65  $\mu\text{mol/mg min}$  and 1.1, respectively (Table 1). Therefore, under steady-state conditions, the ATPase inhibition by CPA is not reversed by addition of higher  $\text{Ca}^{2+}$  concentration (Fig. 2A).

The stoichiometric ratio between  $\text{Ca}^{2+}$  transport and Pi release in the presence of different free  $\text{Ca}^{2+}$  concentrations can be obtained from Fig. 2B. These experiments are suitable to provide information on the coupling phenomenon because the passive permeability of the vesicles to  $\text{Ca}^{2+}$  after the CPA treatment is not increased (data not shown) [17]. The coupling between both processes is given by the slope of the straight

lines, which is  $\sim 1.9$  in control and  $\sim 1.1$  in the presence of CPA. These data clearly show that in control, the  $\text{Ca}^{2+}$ :ATP coupling remains unaltered ( $\sim 2$ ) and in presence of CPA it is reduced ( $\sim 1$ ) within the  $\text{Ca}^{2+}$  concentration range used to saturate the binding sites (Table 1).

### 3.2. $\text{Ca}^{2+}$ binding

In a different set of experiments, the binding of  $\text{Ca}^{2+}$  to the  $\text{Ca}^{2+}$ -ATPase protein under equilibrium conditions was investigated. The incubation medium, with a free  $\text{Ca}^{2+}$  concentration of  $\sim 32 \mu\text{M}$  (pCa 4.5), was supplemented with 1 mM [ $^3\text{H}$ ]glucose in order to evaluate the  $\text{Ca}^{2+}$  actually bound to the protein after the filtration. Thereby, Fig. 3 shows the effect of CPA on the level of  $^{45}\text{Ca}^{2+}$  bound to the  $\text{Ca}^{2+}$ -ATPase. Addition of CPA at a toxin/enzyme molar ratio  $\leq 1$  to the enzyme reduced the maximal  $\text{Ca}^{2+}$  binding ( $\sim 7.5$  nmol/mg of protein) to the half ( $\sim 3.2$  nmol/mg of protein). When CPA above an equimolar level was added, the effect was less sharp. Thus, the  $\text{Ca}^{2+}$  binding capacity tended to decrease and the inhibition was almost complete when the concentration of CPA was increased up to 300  $\mu\text{M}$ .

## 4. Discussion

In the present work, the effect of CPA on  $\text{Ca}^{2+}$ -binding to the SR  $\text{Ca}^{2+}$ -ATPase has been investigated, because most of  $\text{Ca}^{2+}$ -ATPase inhibitors act or affect the  $\text{Ca}^{2+}$ -binding mechanism [16,18]. CPA concentration dependently inhibits the activity of the SR  $\text{Ca}^{2+}$ -ATPase (Fig. 1), as has been shown before [3–5,7,15], and the calculated  $K_{0.5}$  ( $\sim 0.2 \mu\text{M}$ ) and molar ratio ( $\sim 1$ ) are in agreement with those previously published results [5,7,15].

The most important result presented in this study is the demonstration that CPA acts reducing the stoichiometric ratio between  $\text{Ca}^{2+}$  transport and Pi release of the  $\text{Ca}^{2+}$ -ATPase of SR, that is, CPA uncouples ATPase activity. In vesicles derived from rabbit white muscle, the hydrolysis of one ATP molecule leads to the translocation of two  $\text{Ca}^{2+}$  ions across the membrane. This was determined by measuring the ratio between the initial rates of  $\text{Ca}^{2+}$  uptake and ATP hydrolysis (Fig. 2). In the presence of CPA, the uncoupled hydrolysis of  $\text{Ca}^{2+}$ -ATPase promotes a decrease on the  $\text{Ca}^{2+}$ /ATP ratio to values  $\sim 1$ . The data of Fig. 2 and Table 1 show that CPA reduces the  $\text{Ca}^{2+}$ /ATP ratio at all  $\text{Ca}^{2+}$  concentrations tested. This conclusion is also supported by the  $\text{Ca}^{2+}$ -binding experiments (Fig. 3). Thereby, the stoichiometry of the high affinity binding sites was determined and was found to be  $\sim 7.5$  nmol/mg of protein in the absence of CPA (control), which corresponds to two  $\text{Ca}^{2+}$  sites per ATPase monomer, when com-




Fig. 3. Effect of CPA on  $\text{Ca}^{2+}$  binding by  $\text{Ca}^{2+}$ -ATPase. Binding of  $^{45}\text{Ca}^{2+}$  to  $\text{Ca}^{2+}$ -ATPase as a function of CPA concentration at pCa 4.5.

pared with the maximum phosphorylation (data not shown, [16]). In the presence of CPA at molar ratio  $\sim 1$ , the data were  $\sim 3.4$  nmol/mg of protein, which corresponds to one  $\text{Ca}^{2+}$  site per ATPase monomer. In agreement with these data, the Hill coefficient indicates positive cooperativity in the absence of CPA (with two  $\text{Ca}^{2+}$  binding sites) and non-cooperativity in the presence of CPA (with only one site). Therefore, it seems clear that one  $\text{Ca}^{2+}$ -binding site is destroyed. However, this finding was not obtained clearly in a previous work where the  $\text{Ca}^{2+}$  binding to the  $\text{Ca}^{2+}$ -ATPase was also measured after incubation with CPA (see Fig. 1 in [5]), although the experiments were carried out under different conditions.

Previous observations have suggested that CPA interferes with  $\text{Ca}^{2+}$  binding and with the  $\text{Ca}^{2+}$ -induced changes in the conformation of  $\text{Ca}^{2+}$ -ATPase [4,17,19].

The mechanism of action of CPA is quite similar to thapsigargin (TG), the most specific, potent and the best characterized inhibitor of SR  $\text{Ca}^{2+}$ -ATPase [20]. It has been shown that binding of TG to the  $\text{Ca}^{2+}$ -ATPase also results in a change in extent of  $\text{Ca}^{2+}$  binding, from the usual two  $\text{Ca}^{2+}$  ions per ATPase molecule to one [21].

The two  $\text{Ca}^{2+}$  binding sites (I and II) are surrounded by helices M4, M5, M6 and M8 [22], and the N-terminal region of M3 helix plays an important role in controlling the  $\text{Ca}^{2+}$  entry pathway [23]. The CPA-binding domain resides at the membrane interface and interacts with S3 stalk segment (cytoplasmic prolongation of M3) of the  $\text{Ca}^{2+}$ -ATPase [7], which can explain the effect on the  $\text{Ca}^{2+}$ -binding sites. Thereby, changes in the packing of the transmembrane  $\alpha$ -helices result in changes at the  $\text{Ca}^{2+}$ -binding site [24] and large-scale rearrangements of transmembrane helices take place during  $\text{Ca}^{2+}$ -bound and  $\text{Ca}^{2+}$ -free structures transition. As a result, the number of oxygen atoms that can coordinate to  $\text{Ca}^{2+}$  decreases [22] and site I appears to be more intact in the  $\text{Ca}^{2+}$ -free form than site II. It was suggested that in the process of  $\text{Ca}^{2+}$ -binding,  $\text{Ca}^{2+}$  ions pass through site II to reach site I, and that this would only be possible if site II were not properly formed in the absence of  $\text{Ca}^{2+}$  at site I. Comparison of the  $\text{Ca}^{2+}$ -free and  $\text{Ca}^{2+}$ -bound structures suggests that a single binding site for  $\text{Ca}^{2+}$  could exist in the  $\text{Ca}^{2+}$ -free structure [25]. The  $\text{Ca}^{2+}$ -free structure is the equivalent to  $\text{E}_2$  conformation to which the CPA is bound [6]. Therefore, CPA may act stabilizing this conformational state of the  $\text{Ca}^{2+}$ -ATPase that can bind only one  $\text{Ca}^{2+}$ , thus altering the binding affinity and accessibility of the site to  $\text{Ca}^{2+}$ , or could block the access of  $\text{Ca}^{2+}$  to one of the binding sites. However, this is only a speculative model and other possibilities remain open.

The effect of CPA on  $\text{Ca}^{2+}$ -binding of SR  $\text{Ca}^{2+}$ -ATPase described here is additional to the mechanism involved in the inhibition that has been deeply described before [5,6].

*Acknowledgements:* I thank Alicia Torrado for valuable comments on the manuscript.

## References

- [1] DeMeis, L. and Vianna, A.L. (1979) *Ann. Rev. Biochem.* 48, 275–292.
- [2] Holzapfel, C.W. (1968) *Tetrahedron* 24, 2101–2119.
- [3] Goeger, D.E., Riley, R.T., Dorner, J.W. and Cole, R.J. (1988) *Biochem. Pharmacol.* 37, 978–981.
- [4] Seidler, N.W., Jona, I., Vegh, M. and Martonosi, A. (1989) *J. Biol. Chem.* 264, 17816–17823.
- [5] Soler, F., Plenge-Tellechea, F., Fortea, I. and Fernandez-Belda, F. (1998) *Biochemistry* 37, 4266–4274.
- [6] Plenge-Tellechea, F., Soler, F. and Fernandez-Belda, F. (1997) *J. Biol. Chem.* 272, 2794–2800.
- [7] Ma, H., Zhong, L., Inesi, G., Fortea, I., Soler, F. and Fernandez-Belda, F. (1999) *Biochemistry* 38, 15522–15527.
- [8] Eletre, S. and Inesi, G. (1972) *Biochim. Biophys. Acta* 282, 174–179.
- [9] Lowry, O.H., Rosebroogh, N.J., Farr, A.L. and Randall, R.J. (1951) *J. Biol. Chem.* 193, 265–275.
- [10] Fabiato, A. and Fabiato, F. (1979) *J. Physiol.* 75, 463–505.
- [11] Schwartzbach, G., Senn, H. and Anderegg, G. (1957) *Helv. Chim. Acta* 40, 1886–1900.
- [12] Blinks, J., Wier, W., Hess, P. and Prendergast, F. (1982) *Prog. Biophys. Mol. Biol.* 40, 1–114.
- [13] Lin, T. and Morales, M. (1977) *Anal. Biochem.* 77, 10–17.
- [14] Orlowski, S. and Champeil, P. (1991) *Biochemistry* 30, 352–361.
- [15] Schwinger, R.H.G., Brixius, K., Bavendiek, U., Hoischen, S., Muller-Ehmsen, J., Bolck, B. and Erdmann, E. (1997) *J. Pharmacol. Exp. Ther.* 283, 286–292.
- [16] Martínez-Azorín, F., Teruel, J.A., Fernandez-Belda, F. and Gomez-Fernandez, J.C. (1992) *J. Biol. Chem.* 267, 11923–11929.
- [17] Goeger, D.E. and Riley, R.T. (1989) *Biochem. Pharmacol.* 38, 3995–4003.
- [18] Martínez-Azorín, F., Soler, F., Gomez-Fernandez, J.C. and Fernandez-Belda, F. (1995) *Biochem. J.* 309, 499–505.
- [19] Buchet, R., Jona, I. and Martonosi, A. (1992) *Biochim. Biophys. Acta* 1104, 207–214.
- [20] Inesi, G. and Sagara, Y. (1994) *J. Membrane Biol.* 141, 1–6.
- [21] Wictome, M., Henderson, I., Lee, A.G. and East, J.M. (1992) *Biochem. J.* 283, 525–529.
- [22] Toyoshima, C., Nomura, H. and Sugita, Y. (2003) *FEBS Lett.* 555, 106–110.
- [23] Andersen, J.P., Clausen, J.D., Einholm, A.P. and Vilsen, B. (2003) *Ann. N.Y. Acad. Sci.* 986, 72–81.
- [24] Toyoshima, C. and Nomura, H. (2002) *Nature* 418, 605–611.
- [25] Lee, A.G. (2002) *Biochim. Biophys. Acta* 1565, 246–266.